

Index

Note: Page numbers in italics refer to figures and tables.

- Acalculia, rehabilitation, 83
- Acetyl-l-carnitine (ALC), 195
- Acute back pain
- Acute back pain
 - bed rest, 40–41
 - manipulation, 43–44
 - NSAIDs, 41–42
 - surgery
 - ideal timing, 44–45
 - long-term risks, 44
- Acute bacterial meningitis (ABM), 153, 154
- Acute haemorrhagic stroke, treatment
 - craniotomy, 120–121
 - drugs, 121
 - endoscopic evacuation, 120–121
- Acute hydrocephalus
 - and intraventricular haemorrhage, 128
 - management
 - cerebral ventricles, external drainage, 135
 - lumbar puncture, 135
- Acute inflammatory demyelinating polyradiculoneuropathy (AIDP), 244
- Acute ischaemic stroke, treatment
 - anticoagulants, 116–117
 - versus antiplatelet agents, 117
 - antiplatelet agents, 116
 - cooling, 118
 - haemodilution, 117–118
 - HBOT, 118
 - HMG CoA reductase inhibitors, 117
 - neuroprotective agents, 117
- Acute migraine attacks, 29
- Acute respiratory insufficiency (ARI), 239
- Acute stroke
 - acute haemorrhagic stroke, treatment, 120–121
 - acute ischaemic stroke, treatment, 116–118
 - complications, management, 118–119
 - brain oedema, 119–120
 - clot retrieval, 114, 115–116
 - epidemiology, 113
 - mechanism, 113
 - organized stroke unit care, 116
 - pathophysiology, 113
 - secondary prevention, 122
 - thrombolysis, 114–115
 - treatment, 115
- Acute subdural haematoma (ASDH), 128, 142
 - conservative treatment versus surgical evacuation, 143
 - non-operative treatment, 142–143
- Acute traumatic brain injury (TBI)
 - anticonvulsive therapy, 146–147
 - ICP, management, 148–149
 - intracranial hypertension, monitoring, 147–148
 - serial CTs, 143–146
 - traumatic ASDH, non-operative treatment, 142–143
- Acyclovir, 155
- AD, *see* Alzheimer disease
- ADAS-cog score, 216
- ADCS-CGIC score, 216
- Adverse effects measures, in neurology
 - application in clinical practice, 20
 - study types, 19–20
- AEDs, *see* Antiepileptic drugs
- Albendazole, 157
- ALC, *see* Acetyl-l-carnitine
- Almotriptan, 33
- ALS, *see* Amyotrophic lateral sclerosis
- ALS/MND, 234–235
 - diagnosis, 235
 - drugs, 236
- Alzheimer disease (AD), 184, 196
 - mild to moderate dementia, 185–187
 - moderate to severe dementia, 187–188
- Amantadine, 205, 208
- Amino acid, 237
- Amitriptyline, 36, 48, 52, 54
- Amygdalohippocampectomy, 182
- Amyotrophic lateral sclerosis (ALS), 234
- Analgesics, 31, 128–129
- Aneurysmal subarachnoid haemorrhage
 - acute hydrocephalus management, 135
 - cerebral ischaemia
 - management, 134–135
 - prevention, 131–134
 - general care, 128–129
 - poor clinical condition, 127–128
 - rebleeding
 - management, 134
 - prevention, 129–131
 - systemic complications management, 135–136

- Angiotensin-converting enzyme (ACE) inhibitors, 119
- Anticoagulants, 9, 116–117, 123, 124
- Antidepressants, 36, 251
- Antiemetics, 31
- Antiepileptic drugs (AEDs), 36, 173, 147, 251
 for absence seizure, 179
 first-line AEDs, comparison
 partial and generalized epilepsy, 177
 for first seizure, 173–175
 for generalized epilepsy, 176–179
 for partial epilepsy, 175–176
 second-line AEDs, addition of, 179
 withdrawal for people in remission, 179, 181–182
 early versus late discontinuation, 181
 rapid versus slow, 181
 withdrawal versus continued treatment, 179, 181
- Antiplatelet agents, 116
- Antithrombotic agents
 antiplatelet agents, combinations of, 124
 versus antiplatelet agents, for atrial fibrillation, 123
 antiplatelet agents other than aspirin, 124
 versus aspirin, for non-cardiac stroke, 124
 for atrial fibrillation, 123
 for non-cardiac stroke, 123
- Aphasia, rehabilitation of, 79–80
- Apnoea–hypopnoea index (AHI), 71, 239
- Apolipoprotein E e4 allele, 184
- Apraxia, rehabilitation, 82–83
- Aroma therapy, 195
- ASDH, *see* Acute subdural haematoma
- Aspirin, 12, 31, 116, 117, 124, 132, 194
- Astrocytoma, 163
- AT, 131
- Atenolol, 36
- Attention disorders, rehabilitation, 81
- Atypical antipsychotics, 184, 190
- Azathioprine, 225, 231, 260
- Baclofen, 90
 spasticity treatment, 94
- Barthel-ADL index, 71
- BDNF, 234, 237
- Bed rest
 for acute LBP, 40
 versus other treatments, 41
 with sciatica, 41
- Bell's palsy, treatment, 248–249
- Benign paroxysmal positional vertigo (BPPV), 59
 liberatory manoeuvres, 61–64
 recurrences, 64
- Benzodiazepines, 74, 90
- Beta-blockers, 35–36, 119
- Betahistine, 61, 66–67
- Bias, 6, 45
 avoiding, 16–17
- Biopsy, 163–164, 262
- Bischloroethylnitrosourea (BCNU), *see* Carmustine
- 'Black box', 105
- Blood glucose control, 119
- BPPV, *see* Benign paroxysmal positional vertigo
- Brain CTSs policy
 outcomes and management, 144
- Brain metastasis, 161, 168–169
- Brain oedema
 corticosteroids, 120
 craniectomy, 120
 glycerol, 119–120
 mannitol, 119
- Brain tumours, 161
 biopsy, 163–164
 neurological complications, 164
 brain metastasis, 168–169
 chemotherapy, 167–168
 meta-analysis for malignant glioma, 168
 diagnosis, 162–163
 radiation therapy, 165–167
 steroids, 165
- Brandt–Daroff's manoeuvre, 63
- Bromocriptine, 204, 209, 211
- Butulinum toxin (BTX), 90, 95–96, 97
- Cabergoline, 203–204, 211
- Calcium antagonists, 131–132
- Calcium-channel blockers (CCBs), 36–37, 119
- Calcium gene-related peptide (CGRP), 135
- CALM-PD trial, 203
- Canalith jam, 63
- Canalolithiasis hypothesis, 59
- Cannabinoids, 55, 90
- Carbamazepine (CBZ), 50, 146, 175, 176–178
- Carbidopa, 77, 205
- Carmustine, 167
- Carotid stenosis, endovascular treatment, 125
- Carpal tunnel syndrome (CTS), treatment, 252–253
 local corticosteroid injection, 251, 254
 splinting, 251
 surgery, 254
- Cataplexy, 71
 treatment, 73, 74
- Catechol-O-methyltransferase (COMT), 77
 inhibitors, 208–209
- Causality, 5, 19
- CBZ, *see* Carbamazepine
- Central neuropathic pain (CP), 47
 cannabinoids, 55
 lamotrigine, 54
 mexiletine, 55
 opioids, 55
 practical recommendations, 55–56
 presynaptic calcium-channel modulators (PGB/GBP), 54
 sodium-channel blockers, 54
 tricyclic antidepressants, 54
 valproate, 54
- Cerebral ischaemia
 management, 134–135
 induced hypertension, 134

- pharmacological intervention, 135
 - transluminal angioplasty, 134
 - volume expansion, 134
- prevention, 131–134
 - cisternal drainage, 133
 - intracisternal fibrinolysis, 133–134
 - plasma volume, increase of, 133
- treatment, 131
- Cerebral malaria, 156–157
- Chemotherapy, 167–168
- Chloroethylcyclohexylnitrosourea (CCNU), 167
- Cholinesterase inhibitors, 185, 187
 - efficacy and harm, 186
- CIDP, immunotherapy for, 248
- Citalopram, 50
- Clinical Epidemiology (CE), 4
- Clinical practice, 7, 17–19
- Clinical research, 7–8, 16–17
- Clinical wisdom, 13
- Clomipramine, 48
- Clonazepam, 76
- Clonidine, 90
- Clopidogrel, 117, 124
- CLOTS, 118
- Clozapine, 208, 215–216
- CNTF, 234, 237
- Coenzyme Q10 (CoQ10), 37
- Cognitive rehabilitation
 - acalculia, 83
 - aphasia, 79–80
 - apraxia, 82–83
 - attention disorders, 81
 - memory, 81–82
 - SR and RCTs, 84
 - ULN, 80–81
- Combination therapy, 52
- Complementary therapy, 194
 - ALC, 195
 - aroma therapy, 195
 - Ginkgo biloba, 194–195
 - lecithin, 196
 - music therapy, 195–196
 - nicotine, 195
 - phototherapy, 196
- COMT, *see* Catechol-O-methyltransferase
- CONSORT statement, 23
- Continuous outcomes
 - grouped outcome measures, interpretation and usage, 18–19
 - quality of life, 19
- Continuous positive airway pressure (CPAP), 70–71
- Controlled release (CR) oxycodone, 51
- Corticosteroid, 120, 149, 164, 165, 222, 245, 249, 258, 259–260
 - in CNS infections, 151
 - acute bacterial meningitis, 153–155
 - cerebral malaria, 156–157
 - herpes simplex encephalitis, 155
 - Japanese encephalitis, 155–156
 - neurocysticercosis, 157
 - tuberculous meningitis, 151–153
 - for MS, 224
 - for ON, 222–223
 - for relapse treatment, 224
- Cough assist devices, 240
- CT scan, 30–31, 40, 70
- DECIMAL trial, 120
- Deep venous thrombosis (DVT), 129
 - prevention, 118
- Deflazacort, 258, 259
- Dehydroepiandrosterone, 195
- Dementia, treatment, 184
 - agitated behaviour, 188–190
 - complementary therapy, 194–196
 - mild to moderate due to AD, 185–187
 - moderate to severe due to AD, 187–188
 - VaD and VCI, 190–194
- Desipramine, 48
- DESTINY trial, 120
- Dexamethasone, 121, 152, 165
- Diabetic neuropathy (DN), treatment for, 249
 - glycaemic control, 249–250
 - pharmacologic intervention, 250
 - symptomatic treatment, of pain, 250–251
 - options for, 251
- Diagnostic research
 - diagnostic reviews, 23
 - construction, 24
 - critical issues, 24–25
 - importance, 23
 - of systematic reviews, 23–24
- Dichotomous outcomes, 17, 18
 - NNTs, calculation, 18
 - relative versus absolute measures, 17–18
- Diclofenac, 31
- Divalproex sodium, 36, 190
- Donepezil, 185–187, 191, 216–217
- Dopamine agonists, 203–204, 210–212
 - bromocriptine, 204, 211
 - cabergoline, 203–204, 211
 - lisuride, 204
 - pergolide, 210
 - pramipexole, 203, 211
 - ropinirole, 203, 210
 - subcutaneous apomorphine, 211–212
- Duchenne muscular dystrophy (DMD), 258, 259
 - corticosteroid treatment, 258
- Duloxetine, 48, 50
- DVT, *see* Deep venous thrombosis
- EBMitis, 11
- Effectiveness, 5
- Eletriptan, 32, 33
- Endovascular occlusion, 130
- Enoxaparin, 129, 132
- Entacapone, 208, 210

- Epidural steroids
for subacute back pain, 42–43
- Epilepsy, 146, 173
AEDs
for absence seizure, 179
for first seizure, 173–175
for generalized epilepsy, 176–179
for partial epilepsy, 175–176
second-line AEDs, addition of, 179
surgery, 20, 182
amygdalohippocampectomy, 182
lesionectomy, 182
temporal lobectomy, 182
see also Seizure
- Epley manoeuvre, 62, 63
- Ergot derivatives, 34–35
contraindications, 35
ergotamine, 34, 35
- European Atrial Fibrillation Trial (EAFT), 123
- Evidence
causality, 5
proof, 4–5
uncertainty, 8
see also No evidence
- Evidence-based medicine, 3, 11
approach, 6
defined, 3–4
developing and using modes, 5–6
internal and external enemies of, 6–7
lessons learned, 7–8
clinical practice, 7
clinical research, 7–8
health care policies, 8
- Excessive daytime sleepiness, 71, 74
treatment, 72
- Exercise therapy, for chronic back pain, 44
- Expanded disability status scale (EDSS), 221, 231
- Facioscapulohumeral muscular dystrophy, 263
- FASTER trial, 117, 124
- Feeding gastrostomy, 240–242
- Flubiprofen, 31
- Fludrocortisone acetate, 133
- Fluid management, SAH, 128
prophylactic hypervolaemia, 128
- Flunarizine, 36, 37
- Fluoxetine, 36, 50, 74
- Folic acid plus vitamin B, 195
- Forced vital capacity (FVC), 236, 258
- Free radical scavengers
N'-propylenedimicotinamide, 133
tirilazad mesylate, 133
- Free radicals, 237
- Frovatriptan, 32, 33
- Gabapentin (GBP), 50, 90, 179, 237
- Galantamine, 187, 193
- GBP, *see* Gabapentin
- GBS, *see* Guillain–Barré syndrome
- Generalized epilepsy, 176–179
- Gentamicin injection, 65–66
- Ginkgo biloba, 194–195
- Glatiramer acetate, 225, 231
- Glioblastoma multiforme (GBM), 161, 163
- Gliomas, 161, 164, 166
HGG, 161
radiotherapy, 166
LGG, 161
radiation therapy, 165–167, 168
- Guillain–Barré syndrome (GBS), treatment for, 246
corticosteroids, 245
general medical and nursing care, 245–248
intravenous immunoglobulin, 245
plasma exchange, 244–245
- Haemodilution, 117–118, 134
Haemophilus influenzae, 153
- Hallpike manoeuvre, 63
- Haloperidol, 189, 190
- Hamlet, 120
- Headache
classification, 29, 30
CT scan, 30–31
- Health care policies, 8
- Heart rhythm disorders, 136
- HeMMi trial, 120
- Heparinoids, 9, 116, 129, 132
- Herpes simplex encephalitis (HSE), 155
- HMG CoA reductase inhibitors (statins), 14, 117, 132–133
- Homeopathy, 195
- Hydrocortisone, 133, 154
- Hyperbaric oxygen therapy (HBOT), 118
- Hyperfractionation, 165
- Hypertension, 121
- Hyperventilation, 148–149
- Hyponatraemia, 135–136
- Ibuprofen, 31
- ICP, management, 148–149
corticosteroids, 149
hyperventilation, 148–149
mannitol, 149
- Idiopathic hypersomnia, with and without long sleep time, 74–75
- IGF, 236
- Immunoglobulins, 230, 231
- Immunotherapy
for disability progression, 230–231
for relapses prevention, 225–230
- Inclusion body myositis (IBM), 262
- Insomnia, in Parkinson's disease, 76–77
- Interferon, 225, 230–231
for CISs, 224–225
- Interferon alpha, 155
- International Classification of Health and Functioning, 101
- International Classification of Impairments, Disabilities and Handicaps (ICIDH), 101
- Interventional Management of Stroke Study (IMS-3), 114

- Intra-arterial (IA) thrombolysis, 114–115
 Intracerebral haematoma, 127–128, 135
 Intracisternal fibrinolysis, 133–134
 Intravenous (IV) thrombolysis, 114
 Intravenous immunoglobulin, 245
 Intravenous methylprednisolone (IV MP), 222, 245, 260
 INUS, 5
 Invasive assisted ventilation, 239–240
 Isoniazid, 152
- Japanese encephalitis (JE), 155–156
- Kaplan–Meier estimation, 64
 KPS score, 161
- L-dopa, 77
 Lamotrigine, 51, 54, 179, 237
 Lazabemide, 200
 LBP, *see* Low back pain
 Lecithin, 196
 Lesionectomy, 182
 Levetiracetam, 179
 Levodopa
 controlled-release formulations, 204
 motor complications, 205–212
 standard levodopa, 204
 Levorphanol, 55
 Liberatory manoeuvres
 effectiveness of, 61–63
 failure of treatment, 64
 side effects of, 63–64
 supplementary procedures, 63
 Limb-girdle muscular dystrophies (LGMD), 259
 Lisuride, 204
 Louis, Alexandre, 4
 Low back pain (LBP), 40
 bed rest, for acute back pain, 40–41
 epidural steroids, for subacute back pain, 42–43
 exercise therapy, for chronic back pain, 44
 manipulation, for acute back pain, 43–44
 NSAIDs, for acute back pain, 41–42
 surgery, 44–45
 Low-molecular-weight heparins, 116
 LTG, *see* Lamotrigine
 Lumbar disc prolapse, surgery, 45
- Mackie, John, 5
 Magnesium, 37
 Magnesium sulphate, 132
 Mannitol, 119, 149
 MAO-B inhibitors, 200–203, 209–210
 McDonald criteria, 221
 Mechanical clot retrieval, 115–116
 Mechanical embolus removal in cerebral ischaemia (MERC)
 trial, 115
 Medicine d’Observation, 4
 Melatonin, 76
 Memantine, 185, 188, 193–194
 efficacy and harm, 188
- Memory, rehabilitation of, 81
 assistive electronic technologies, use of, 82
 external memory aids, use of, 82
 internal memory aids, use of, 82
 Menière’s disease (MD), 61
 betahistidine, 66–67
 intratympanic gentamicin injection, 65–66
 MESS study, 173
 Methadone, 53
 Methotrexate, 262
 Methylguanine methyltransferase (MGMT), 167
 Methylphenidate, 74, 75
 Methylprednisolone, 64, 251
 Methysergide, 37
 Metoprolol, 36, 37
 Mexiletine, 52, 55
 Midazolam, 128
 Migraine
 non-specific acute treatments, 31
 antiemetics, 31
 analgesics and NSAID, 31
 prognosis, 37
 prophylaxis, 35–37
 antidepressants, 36
 antiepileptic drugs/neuromodulators, 36
 behavioural therapy, 37
 beta-blockers, 35–36
 calcium-channel blockers, 36–37
 herbs and vitamins, 37
 methysergide and pizotifen, 37
 physical treatments, 37
 sinusitis, 30
 specific acute treatments, 31–35
 ergot derivatives, 34–35
 triptans, 32–34
 Mild to moderate dementia, treatment of, 185–187
 Mini-Mental State Examination (MMSE) scale, 71, 215, 217
 Minocycline, 237
 Misonidazole, 167
 Mitoxantrone, 225–230, 231
 MND, *see* Motor neurone diseases
 Modafinil, 74, 75
 Moderate to severe dementia, treatment of, 187–188
 Montgomery-Asberg-Depression-Rating Scale (MADRS), 71
 Morphine, 52
 Motor neurone diseases (MND), 234
 cough assist devices, 240
 MI-E device, 240
 feeding gastrostomy, 240–242
 invasive assisted ventilation, 239–240
 NIPPV, 238
 pharmacological treatment, 235–238
 respiratory function assessment, 238
 ‘Multi-modal therapy with an exercise focus’, 44
 Multiple sclerosis (MS)
 CISs, interferon for, 224–225
 corticosteroids, 224
 disability progression, immunotherapy for, 230–231
 relapses prevention, immunotherapy for, 225–230

- Multiple sleep latency test (MSLT), 71
- Muscle disorders
 - Duchenne muscular dystrophy, 258–259
 - facioscapulohumeral muscular dystrophy, 263
 - limb-girdle muscular dystrophies (LGMDs), 59
 - myasthenia gravis, 259–261
 - polymyositis, 261–263
- Music therapy, 195–196
- Myasthenia gravis
 - corticosteroid, 259–260
 - with azathioprine, 260
 - immunosuppressive treatments, 260–261
 - thymectomy, 261
- Nadolol, 36
- Naproxen, 31
- Naratriptan, 32
- Narcolepsy, with and without cataplexy, 71–74
 - MSLT, 71
- Neisseria meningitidis*, 153
- Neurocysticercosis (NCC), 157
 - extraparenchymal NCC, 157
 - parenchymal NCC, 157
- Neurogenic pulmonary oedema, 136
- Neurolinguistic-cognitive approach, 80
- Neurological sequelae, 154
- Neurology, outcome measures
 - application, in clinical practice
 - continuous outcomes, 18–19
 - dichotomous outcomes, 17–18
 - application, in clinical research
 - assessor's viewpoint, 17
 - measurement bias, avoiding, 16–17
 - placebos and blinding, 17
 - example, 20
 - primary and secondary outcomes, defining, 15
 - standardizing, 15
 - statistical versus clinical significance, 16
 - surrogate outcomes, 15–16
- Neuromodulators, 36
- Neuropathic pain, 47
 - central pain, 54–56
 - net gain, 48
 - painful neuropathy, 48–52
 - posttherapeutic neuralgia, 52–54
 - reliability, 48
- Neuroprotective agents, 117
- Neurorehabilitation
 - beneficiary, 103–105
 - health service organization and policy, implications for, 105–106
 - outcomes, 100–101
 - research, implications for, 106
 - searching evidence, general approach, 101
 - specialist rehabilitation service, 105
 - timing and intensity, 101–103
- Nicardipine, 131, 132, 134
- Nicotine, 195
- Nifedipine, 37
- Nimodipine, 131–132
- NIPPV, *see* Non-invasive positive pressure ventilation
- Nitric oxide, 155
- Nitrosourea, 167, 168
- Nizofenone, 133
- NMDA, 187, 191
- NMDA-antagonists, 52, 54
- NNTs
 - calculation, 18
- No evidence
 - clinical trial, joining to, 13–14
 - clinical wisdom, 13
 - confirmation, 12
 - EBMitis, avoid succumb to, 11
 - generalization, with available evidence, 12
 - non-randomized evidence from good observational studies, 12
 - pathophysiology, relying on, 12–13
 - therapeutic nihilism, avoid succumb to, 14
 - see also* Evidence
- Non-invasive positive pressure ventilation (NIPPV), 238–239
- Non-randomized evidence
 - from good observational studies, 12
- Non-rheumatic atrial fibrillation (NRAF), 123
- Non-specific acute treatments
 - analgesics and NSAID, 31
 - antiemetics, 31
- Nordic Cooling Stroke Study (NOCSS), 118
- Nortriptyline, 48, 52
- NSAIDs, for acute back pain, 41–42
 - with other control, comparison, 42
- Olanzapine, 215–216
- Oligodendroglioma, 163
- Opioids, 53
- Optic neuritis (ON), 221
 - corticosteroids, 222–223
- Optic Neuritis Treatment Trial (ONTT), 222
- Organized stroke unit care, 116
- Oxcarbazepine (OXC), 50–51, 179
- Painful polyneuropathy (PPN), 47
 - combination therapy, 52
 - lamotrigine, 52–53
 - mexiletin, 52
 - NMDA-antagonists, 52
 - opioids, 53
 - practical recommendations, 54
 - presynaptic calcium-channel modulators, 50
 - selective serotonin reuptake inhibitors, 50
 - serotonin–noradrenaline reuptake inhibitors, 48–50
 - sodium-channel blockers, 50–51
 - TCA, 48
 - topical capsaicin, 54
 - topiramate, 51
 - treatments, 49
 - valproate, 51, 54
- Pallidotomy, 214–215
- Papaverine, 134
- Paracetamol, 31, 128

- Parkinson's disease (PD), 199
 and psychosis
 clozapine, 215
 olanzapine, 215–216
 quetiapine, 215
 early PD
 dopamine agonists, 203, 210
 levodopa, 204
 MAO-B inhibitors, 200–203
 levodopa-induced motor complications
 amantadine, 205, 208
 clozapine, 208
 COMT inhibitors, 208–209
 controlled-released levodopa, 205
 dopamine agonists, 210–212
 MAO-B inhibitors, 209–210
 PDD
 rivastigmine, 216–217
 surgery
 ablative, 214–215
 stimulation, 212–214
 Parkinson's disease dementia (PDD), 216–217
 Paroxetine, 50
 Partial epilepsy, 175–176
 Paternalism, 7
 Pathophysiology, 4–5, 113
 relying on, 12–13
 PD, *see* Parkinson's disease
 Percutaneous endoscopic gastrostomy (PEG), 240, 241, 242
 Pergolide, 210
 Peripheral nerve disorders
 Bell's palsy, treatment for, 248–249
 CIDP, immunotherapy for, 248
 CTS, treatment for, 251–254
 DN, treatment for, 249–251
 symptomatic treatment, 250–251
 GBS, treatment for, 244–248
Petasites hybridus, 37
 Pharmacological treatment, 185, 187, 188, 190
 for motor neurone disorders, 235–238
 for rebleeding, 130–131
 Phenobarbital, 175–176, 178
 Phenobarbitone, 146
 Phenol, 90
 Phenytoin, 50, 146, 176, 178
 Phototherapy, 196
 Piritramide, 128
 Piroxicam, 31
 Pizotifen, 37
 Plasma exchange (PE), 244–245
Plasmodium falciparum, 156
 Polymyositis, 261–263
 second line treatments, 263
 Poor clinical condition
 acute hydrocephalus and intraventricular
 haemorrhage, 128
 acute subdural haematoma, 128
 intracerebral haematoma, 127–128
 Porch Index of Communicative Abilities (PICA), 80
 Postherpetic neuralgia (PHN), 47, 52–54
 capsaicin, 54
 NMDA-antagonists, 54
 opioids, 53
 practical recommendations, 54
 presynaptic calcium-channel modulators (PGB/GBP), 53
 TCA antidepressants, 52
 topical lidocaine, 54
 treatments, 53
 valproate, 54
 Post-Stroke Rehabilitation Outcomes Project (PSROP), 105
 Post-traumatic epilepsy, 146
 Post-traumatic seizures (PTS), 146
 Practical recommendations, 53–54
 for CP, 55–56
 for PHN, 54
 for PPN, 52
 Pramipexole, 76, 203, 211
 Prednisolone, 152, 258, 260
 Prednisone, 222, 258
 Pregabalin (PGB), 50
 Presto trial, 210
 Presynaptic calcium-channel modulators
 for CP, 54
 for PHN, 53
 for PPN, 50
 Preventive volume expansion therapy, 133
 Primary and secondary outcomes, defining, 15
 Procarbazine chloroethylcyclohexylnitrosourea vincristine
 (PCV), 167
 Prognosis, 37
 of acute migraine attacks, 37
 of brain tumours, 161
 of herpes simplex encephalitis, 155
 of traumatic ASDH, 143
 Proof, 3, 4–5
 Prophylaxis, of acute migraine attacks
 antidepressants, 36
 antiepileptic drugs/neuromodulators, 36
 behavioural therapy, 37
 beta-blockers, 35–36
 calcium-channel blockers, 36–37
 guidelines, 35
 herbs and vitamins, 37
 methysergide and pizotifen, 37
 physical treatments, 37
 Propranolol, 35–36, 37
 Prostacyclin, 119
 Psychosis, 215–216
 Pyrazinamide, 152
 Pyridoxine, 152
 QUADAS tool, 25
 Quality of life, 19, 182
 Quetiapine, 215
 Quinine, 156
 Radiation therapy, 165–167
 Radiologically inserted gastrostomy (RIG), 241–242

- Randomized control trials (RCTs), 5, 23, 47, 90, 167, 170, 182, 236
- Rasagiline, 200, 209–210, 212, 217
- REAL-PET study, 203
- Rebleeding, aneurysmal SAH
 endovascular occlusion, 130
 management
 emergency occlusion, 134
 resuscitation, 134
 pharmacological treatment, 130–131
 antifibrinolytic agents, 131
 recombinant factor VIIa, 131
 prevention, 129
 surgical occlusion, 130
 treatment, 129
- Receiver-operating characteristic (ROC) curve, 25
- REM sleep behaviour disorder (RBD)
 in Parkinson's disease, 75–76
- Respiratory function assessment, 238, 241
- Respiratory muscle strength (RMS), 238
- Ribavirin, 155
- Riboflavin (vitamin B2), 37
- Rifampicin, 152
- Riluzole, 13, 234, 236, 242
- Rivastigmine, 187, 193, 216–217
- Rizatriptan, 32, 33
- Ropinirole, 203, 210
- Sciatica, 40
- Seizure, 20, 146–147, 157
 first seizure, treatment, 173–174, 175
see also Epilepsy
- Selective serotonin reuptake inhibitors (SSRIs), 36, 50, 74
- Selegiline, 200, 209
- Semont's manoeuvre, 63
- Serotonin–noradrenaline reuptake inhibitors (SNRI), 48, 50
- Serum lipid, 121, 123
- Simvastatin, 117, 123
- Sleep apnoea syndrome, 70–71
- Sleep disorders
 idiopathic hypersomnia, with and without long sleep time, 74–75
 insomnia in Parkinson's disease, 76–77
 narcolepsy, with and without cataplexy, 71–72
 RBD in Parkinson's disease, 75–76
 sleep disordered breathing and stroke, 70–71
 CPAP, 70–71
- Slow vital capacity (SVC), 242
- Sodium oxybate, 74
- Sodium valproate (VPA), 175, 176, 178
- Sodium-channel blockers, 50–51
- Spacing-of-repetitions procedure, 82
- Spasticity, 89
 BTX, 90, 95–96, 97
 intrathecal drugs, 90
 oral anti-spasticity drugs, 90
 oral drug treatments, 92–93
 physical interventions, 91
 physiotherapy, 89–90
- Spatiomotor, 80
- Specific acute treatments
 ergot derivatives, 34–35
 triptans, 32–34
- Spinal fusion surgery, 45
- SSRIs, *see* Selective serotonin reuptake inhibitors
- STARD initiative, 23, 24
- Statins, 117, 132–133
- Stem cell therapy, 242
- Stereotactic radiosurgery (SRS), 162, 166, 169
- Steroids
 for brain tumours, 165
- Stimulation surgery
 pallidal (GPi) stimulation, 212–213
 subthalamic nucleus, 213
- Streptococcus pneumoniae*, 153
- Stroke, secondary prevention
 antithrombotic agents, 123–124
 carotid stenosis, endovascular treatment for, 125
 risk factor modification, 121–123
 symptomatic carotid stenosis, endarterectomy, 124–125
- Studio Italiano Fibrillazione Atriale (SIFA) trial, 123
- Subarachnoid haemorrhage (SAH), 127, 131, 133, 143
- Subcutaneous apomorphine, 211–212
- Sumatriptan, 32, 33
- Summary ROC (sROC) curve, 25
- Surgical occlusion, 130
- Symptomatic carotid stenosis, endarterectomy, 124–125
- Systemic complications management, 135–136
 heart rhythm disorders, 136
 hyponatraemia, 135–136
 neurogenic pulmonary oedema, 136
- Tacrolimus, 260
- Taenia solium*, 157
- TBM, *see* Tuberculous meningitis
- Temozolomide, 167, 168
- Tempo trial, 200
- Temporal lobectomy, 182
- Terms of reference, 3
- Tetrahydrocannabinol (THC), 55
- Thienopyridines, 124
- Thymectomy, 261
- Tiagabine, 179
- Timolol, 36
- Tirilazad, 133
- Tizanidine, 90
- Tolcapone, 208–209, 217
- Tolfenamic acid, 31
- Tolperisone, 90
- Tonic clonic seizures, 178
- Topical capsaicin, 52, 54
- Topiramate, 36
- Tramadol, 52, 53, 128
- Transient ischaemic attack (TIA), 113, 163
- Transluminal angioplasty, 134
- Traumatic brain injury (TBI), 79, 100, 103, 142, 143, 147
- Trazodone, 189
- Tricyclic antidepressants (TCA), 48, 54, 74, 77

- Triptans, 14, 32–34
 - contraindications, 33
 - efficacies, 32–33
 - guidelines, 33
 - meta-analysis, 34
 - uses, 34
- Tromethamine (THAM), 148, 149
- Tuberculous meningitis (TBM), 151
 - grades, 152
- Uncertainty, 5, 130
- Unfractionated heparin (UFH), 9, 116, 117
- Unilateral neglect (ULN), 79
 - rehabilitation of, 80–81
- Upper motor neurone (UMN) syndrome, 89, 235, 91
- Valacyclovir, 64
- Valproate, 36, 51, 54, 147
- Valproic acid, 189–190
- Vascular dementia (VaD), 184, 190
 - cholinergic deficits, 190
 - subtypes, 190
 - treatment, 190–194
- Venlafaxine, 48, 50
- Verapamil, 36, 37, 134
- Vertigo and dizziness, 59
 - BPPV, 59, 61, 63, 64
 - MD, 61, 65
 - VN, 59–61
- Vestibular neuritis (VN), 59–61
 - corticosteroids, 64
 - treatment for, 65
 - vestibular tonus imbalance, for physical therapy, 64–65
- Vestibulotoxic drugs, 61
- Vigabatrin, 179
- Visual scanning training, 80, 81
- Visuomotor, 80
- Whose brain radiotherapy (WBRT), 162, 169, 170
- Xaliproden, 234, 237–238
- Zolmitriptan, 32
- Zonisamide, 179

